Media coverage about SCYNEXIS (NASDAQ:SCYX) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SCYNEXIS earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.8401242166754 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- SCYNEXIS, Inc. (SCYX) – Momentum Stock in Focus | Wallstreet … - Wall Street Morning (wallstreetmorning.com)
- Are Investors Shying Away from SCYNEXIS, Inc. (NASDAQ:SCYX)? - FLBC News (flbcnews.com)
- Insider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock (americanbankingnews.com)
- SCYNEXIS : Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (4-traders.com)
- SCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
SCYNEXIS (SCYX) traded up 0.61% during mid-day trading on Friday, reaching $1.66. 223,467 shares of the company were exchanged. The firm’s market capitalization is $44.36 million. The stock has a 50-day moving average of $1.74 and a 200 day moving average of $2.30. SCYNEXIS has a 1-year low of $1.52 and a 1-year high of $5.51.
SCYX has been the topic of a number of research reports. Needham & Company LLC downgraded shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. Aegis restated a “buy” rating on shares of SCYNEXIS in a report on Tuesday, May 30th. Zacks Investment Research cut shares of SCYNEXIS from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Roth Capital started coverage on shares of SCYNEXIS in a report on Monday, July 10th. They issued a “buy” rating and a $8.50 price target on the stock. Finally, ValuEngine upgraded shares of SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $10.22.
WARNING: “SCYNEXIS (NASDAQ:SCYX) Earns Media Impact Rating of 0.18” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/19/scynexis-nasdaqscyx-earning-somewhat-positive-press-coverage-report-shows-updated.html.
In other SCYNEXIS news, Director David C. Hastings bought 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The stock was purchased at an average price of $1.75 per share, for a total transaction of $35,000.00. Following the purchase, the director now directly owns 20,000 shares in the company, valued at $35,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have bought 40,000 shares of company stock valued at $66,600. 3.91% of the stock is currently owned by corporate insiders.
About SCYNEXIS
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
